Literature DB >> 19647433

Amyloids in bacterial inclusion bodies.

Natalia S de Groot1, Raimon Sabate, Salvador Ventura.   

Abstract

Protein misfolding and aggregation into amyloid structures are associated with dozens of human diseases. Recent studies have provided compelling evidence for the existence of highly ordered, amyloid-like conformations in the insoluble inclusion bodies produced during heterologous protein expression in bacteria. Thus, amyloid aggregation seems to be an omnipresent process in both eukaryotic and prokaryotic organisms. Amyloid formation inside cell factories raises important safety concerns with regard to the toxicity and infectivity of recombinant proteins. Yet such findings also suggest that prokaryotic cells could be useful systems for studying how and why proteins aggregate in vivo, and they could also provide a biologically relevant background for screening therapeutic approaches to pathologic protein deposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647433     DOI: 10.1016/j.tibs.2009.03.009

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  48 in total

1.  Mammalian prion amyloid formation in bacteria.

Authors:  Bruno Macedo; Yraima Cordeiro; Salvador Ventura
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

Review 2.  Towards revealing the structure of bacterial inclusion bodies.

Authors:  Lei Wang
Journal:  Prion       Date:  2009-07-25       Impact factor: 3.931

3.  Direct Conversion of an Enzyme from Native-like to Amyloid-like Aggregates within Inclusion Bodies.

Authors:  Francesco Elia; Francesca Cantini; Fabrizio Chiti; Christopher Martin Dobson; Francesco Bemporad
Journal:  Biophys J       Date:  2017-06-20       Impact factor: 4.033

Review 4.  Suppression and dissolution of amyloid aggregates using ionic liquids.

Authors:  Takahiro Takekiyo; Yukihiro Yoshimura
Journal:  Biophys Rev       Date:  2018-04-25

5.  Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin.

Authors:  Susan D Orwig; Christopher W Perry; Laura Y Kim; Katherine C Turnage; Rong Zhang; Douglas Vollrath; Ingeborg Schmidt-Krey; Raquel L Lieberman
Journal:  J Mol Biol       Date:  2011-12-13       Impact factor: 5.469

6.  RepA-WH1 prionoid: a synthetic amyloid proteinopathy in a minimalist host.

Authors:  Rafael Giraldo; Susana Moreno-Díaz de la Espina; M Elena Fernández-Tresguerres; Fátima Gasset-Rosa
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

7.  The Skp chaperone helps fold soluble proteins in vitro by inhibiting aggregation.

Authors:  Kevin C Entzminger; Christine Chang; Ryan O Myhre; Katie C McCallum; Jennifer A Maynard
Journal:  Biochemistry       Date:  2012-06-08       Impact factor: 3.162

8.  Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formation.

Authors:  Yuichi Yoshimura; Yuxi Lin; Hisashi Yagi; Young-Ho Lee; Hiroki Kitayama; Kazumasa Sakurai; Masatomo So; Hirotsugu Ogi; Hironobu Naiki; Yuji Goto
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

9.  Amyloid-like protein inclusions in tobacco transgenic plants.

Authors:  Anna Villar-Piqué; Raimon Sabaté; Oriol Lopera; Jordi Gibert; Josep Maria Torne; Mireya Santos; Salvador Ventura
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

10.  Characterization of the amyloid bacterial inclusion bodies of the HET-s fungal prion.

Authors:  Raimon Sabaté; Alba Espargaró; Sven J Saupe; Salvador Ventura
Journal:  Microb Cell Fact       Date:  2009-10-28       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.